EC Number   |
Application |
Reference |
|---|
   3.4.22.40 | medicine |
- |
36716, 36717, 36719, 36728 |
| 3.4.22.40 | medicine |
ectopic expression of enzyme alters processing of amyloid precursor protein and increases significantly release of beta-amyloid |
651220 |
| 3.4.22.40 | medicine |
ectopic expression of enzyme increases the secretion of amyloid precursor protein, increase is blocked in mutant C73S |
649572 |
| 3.4.22.40 | medicine |
is thought to be the major cause of tumor cell resistance to bleomycin chemotherapy |
36721 |
| 3.4.22.40 | medicine |
patient study, patients with testicular germ-cell cancer treated with bleomycin-containing chemotherapy, response to chemotherapy determined by gene polymorphisms involved in metabolism of cytotoxic drugs analyzed, importance for risk classification and selection for alternative treatment strategies suggested |
683707 |
| 3.4.22.40 | medicine |
the bleomycins (BLMs) are widely used in combination therapies for the treatment of various cancers. Dose-dependent and cumulative pulmonary toxicity is the major cause of BLM-associated morbidity, limiting the broad uses of BLMs as anticancer drugs. Opportunities to overcome bleomycin-induced pulmonary toxicity in chemotherapies, potentially by exploring BLM B2 as the preferred congener, engineering designer bleomycins with optimized activity for recombinant human bleomycin hydrolase (rhBLMH), or co-administrating rhBLMH directly into the lung as a potential protein therapeutic |
753009 |
